Fig. 1From: Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnosticsMonthly patient numbers by assay group and assay type analysed at PMCC since 2013. Amplicon assays have been used throughout while hybrid capture assays were introduced in 2017Back to article page